Genetic instability of live, attenuated human immunodeficiency virus type 1 vaccine strains

Journal of Virology

Volumn 73, Issue 2, 1999, Pages 1138-1145

  Berkhout, Ben ^a,b   Verhoef, Koen ^a   Van Wamel, Jeroen L B ^a   Back, Nicole K T ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NUCLEOTIDE; TRANSCRIPTION FACTOR SP1;

ARTICLE; BINDING SITE; DRUG SAFETY; GENE DELETION; GENETIC STABILITY; HUMAN IMMUNODEFICIENCY VIRUS 1; LONG TERMINAL REPEAT; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; VIRUS GENE; VIRUS GENOME;

EID: 0032932711     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.73.2.1138-1145.1999     Document Type: Article

References (60)

1. Adachi, A., H. E. Gendelman, S. Koenig, T. Folks, R. Willey, A. Rabson, and M. A. Martin. 1986. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 59:284-291.
2. Almond, N., K. Kent, M. Cranage, E. Rud, B. Clarke, and E. J. Stott. 1995. Protection by attenuated simian immunodeficiency virus in macaques against challenge with virus-infected cells. Lancet 345:1342-1344.
3. Baba, T. W., Y. S. Jeong, D. Penninck, R. Bronson, M. F. Greene, and R. M. Ruprecht. 1995. Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques. Science 267:1820-1825.
4. Back, N. K. T., M. Nijhuis, W. Keulen, C. A. B. Boucher, B. B. Onde Essink, A. B. P. van Kuilenburg, A. H. Van Gennip, and B. Berkhout. 1996. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J. 15:4040-4049.
5. Berkhout, B., B. Klaver, and A. T. Das. 1997. Forced evolution of a regulatory RNA helix in the HIV-1 genome. Nucleic Acids Res. 25:940-947.
6. Berkhout, B., and J. L. B. van Wamel. 1996. Role of the DIS hairpin in replication of human immunodeficiency virus type I. J. Virol. 70:6723-6732.
7. Birmigham, K. 1997. AIDS vaccine trial:publicity stunt or genuine attempt at progress? Nat. Med. 3:1055-1056.
8. Chang, L. J., E. McNulty, and M. Martin. 1993. Human immunodeficiency viruses containing heterologous enhancer/promoters are replication competent and exhibit different lymphocyte tropisms. J. Virol. 67:743-752.
9. Chen, B. K., M. B. Feinberg, and D. Baltimore. 1997. The κB sites in the human immunodeficiency virus type I long terminal repeat enhance virus replication yet are not absolutely required for viral growth. J. Virol. 71:5495-5504.
10. Cohen, J. 1997. Novel campaign to test live HIV vaccine. Science 277:1035.
11. Croteau, G., L. Doyon, D. Thibeault, G. McKercher, L. Pilote, and D. Lamarre. 1997. Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors. J. Virol. 71:1089-1096.
12. Daniel, M. D., F. Kirchhoff, S. C. Czajak, P. K. Sehgal, and R. C. Desrosiers. 1992. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 258:1938-1941.
13. Das, A. T., B. Klarer, and B. Berkhout. 1995. Reduced replication of human immunodeficiency virus type 1 mutants that use reverse transcription primers other than the natural tRNA(3Lys). J. Virol. 69:3090-3097.
14. Das, A. T., B. Klaver, B. I. F. Klasens, J. L. B. van Wamel, and B. Berkhout. 1997. A conserved hairpin motif in the R-U5 region of the human immunodeficiency virus type 1 RNA genome is essential for replication. J. Virol. 71:2346-2356.
15. Das, A. T., A. P. van Dam, B. Klaver, and B. Berkhout. 1998. Improved envelope function selected by long-term cultivation of a translation-impaired HIV-1 mutant. Virology 244:552-562.
16. Deacon, N. J., A. Tsykin, A. Solomon, K. Smith, M. Ludford-Menting, D. J. Hooker, D. A. McPhee, A. L. Greenway, A. Ellett, C. Chatfield, V. A. Lawson, S. Crowe, A. Maerz, S. Sonza, J. Learmont, J. S. Sullivan, A. Cunningham, D. Dwyer, D. Dowton, and J. Mills. 1995. Genomic structure of an attenuated quasispecies of HIV-1 from blood transfusion donor and recipients. Science 270:988-991.
17. Desrosiers, R. C. 1992. HIV with multiple gene deletions as a live attenuated vaccine for AIDS. AIDS Res. Hum. Retroviruses 8:411-421.
18. Domingo, E., and J. J. Holland. 1997. RNA virus mutations and fitness for survival. Annu. Rev. Microbiol. 51:151-178.
19. Dynan, W. S. 1989. Modularity in promoters and enhancers. Cell 58:1-4.
20. Gibbs, J. S., A. A. Lackner, S. M. Lang, M. A. Simon, P. K. Sehgal, M. D. Daniel, and R. C. Desrosiers. 1995. Progression to AIDS in the absence of a gene for Vpr or Vpx. J. Virol. 69:2378-2383.
21. Gibbs, J. S., D. A. Regier, and R. C. Desrosiers. 1994. Construction and in vitro properties of HIV-1 mutants with deletions in "nonessential" genes. AIDS Res. Hum. Retroviruses 10:343-350.
22. Goh, W. C., M. E. Rogel, C. M. Kinsey, S. F. Michael, P. N. Fultz, M. A. Nowak, B. H. Hahn, and M. Emerman. 1998. HIV-1 Vpr increases viral expression by manipulation of the cell cycle: a mechanism for selection of Vpr in vivo. Nat. Med. 4:65-71.
23. Grez, M., M. Zörnig, J. Nowock, and M. Ziegler. 1991. A single point mutation activates the Moloney murine leukemia virus long terminal repeat in embryonal stem cells. J. Virol. 65:4691-4698.
24. Gustafson, T. A., and L. Kedes. 1989. Identification of multiple proteins that interact with functional regions of the human cardiac α-actin promoter. Mol. Cell. Biol. 9:3269-3283.
25. Harrich, D., G. Mavankal, A. Mette-Snider, and R. B. Gaynor. 1995. Human immunodeficiency virus type 1 TAR element revenant viruses define RNA structures required for efficient viral gene expression and replication. J. Virol. 69:4906-4913.
26. Harrigan, P. R., S. Bloor, and B. A. Larder. 1998. Relative replication fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro. J. Virol. 72:3773-3778.
27. Herr, W., and J. Clarke. 1986. The SV40 enhancer is composed of multiple functional elements that can compensate for one another. Cell 45:461-470.
28. Hoch, J., S. M. Lang, M. Weeger, C. Stahl-Hennig, C. Coulibaly, V. Dittmer, G. Hunsmann, D. Fuchs, J. Muller, S. Sopper, B. Fleckenstein, and K. T. Uberla. 1995. Vpr deletion mutant of simian immunodeficiency virus induces AIDS in rhesus monkeys. J. Virol. 69:4807-4813.
29. Ilyinskii, P. O., and R. C. Desrosiers. 1996. Efficient transcription and replication of simian immunodeficiency virus in the absence of NF-κB and Sp1 binding elements. J. Virol. 70:3118-3126.
30. Jeang, K. T., R. Chun, N. H. Lin, A. Gatignol, C. G. Glabe, and H. Fan. 1993. In vitro and in vivo binding of human immunodeficiency virus type 1 Tat protein and Sp1 transcription factor. J. Virol. 67:6224-6233.
31. Jones, K. A., J. T. Kadonaga, P. A. Luciw, and R. Tjian. 1986. Activation of the AIDS retrovirus by the cellular transcription factor Sp1. Science 232: 755-759.
32. Klaver, B., and B. Berkhout. 1994. Evolution of a disrupted TAR RNA hairpin structure in the HIV-1 virus. EMBO J. 13:2650-2659.
33. Klaver, B., and B. Berkhout. 1994. Comparison of 5′ and 3′ long terminal repeat promoter function in human immunodeficiency virus. J. Virol. 68: 3830-3840.
34. Koken, S. E. C., J. L. van Wamel, J. Goudsmit, B. Berkhout, and J. L. Geelen. 1992. Natural variants of the HIV-1 long terminal repeat: analysis of promoters with duplicated DNA regulatory motifs. Virology 191:968-972.
35. Liang, C., L. Rong, M. Laughrea, L. Kleiman, and M. A. Wainberg. 1998. Compensatory point mutations in the human immunodeficiency virus type 1 Gag region that are distal from deletion mutations in the dimerization initiation site can restore viral replication. J. Virol. 72:6629-6636.
36. Lohman, B. L., M. B. McChesney, C. J. Miller, E. McGowan, S. M. Joye, K. K. van Rompay, E. Reay, L. Antipa, N. C. Pedersen, and M. L. Marthas. 1994. A partially attenuated simian immunodeficiency virus induces host immunity that correlates with resistance to pathogenic virus challenge. J. Virol. 68:7021-7029.
37. Montano, M. A., V. A. Novitsky, J. T. Blackard, N. L. Cho, D. A. Katzenstein, and M. Essex. 1997. Divergent transcriptional regulation among expanding human immunodeficiency virus type 1 subtypes. J. Virol. 71:8657-8665.
38. Murphey-Corb, M. 1997. Live-attenuated HIV vaccines: how safe is safe enough. Nat. Med. 3:17-18.
39. Pagtakhan, A. S., and S. E. Tong-Starksen. 1997. Interactions between Tat of HIV-2 and transcription factor Sp1. Virology 238:221-230.
40. Parrott, C., T. Seidner, E. Duh, J. Leonard, T. S. Theodore, A. J. Buckler-White, M. A. Martin, and A. B. Rabson. 1991. Variable role of the long terminal repeat Sp1 binding sites in human immunodeficiency virus replica-tion in T lymphocytes. J. Virol. 65:1414-1419.
41. Paul, W. E. 1995. Can the immune response control HIV infection? Cell 82: 177-182.
42. Pulsinelli, G. A., and H. M. Temin. 1991. Characterization of large deletions occurring during a single round of retrovirus vector replication: novel deletion mechanism involving errors in strand transfer. J. Virol. 65:4786-4797.
43. Ross, E. K., A. J. Buckler White, A. B. Rabson, G. Englund, and M. A. Martin. 1991. Contribution of NF-κB and Sp1 binding motifs to the replicative capacity of human immunodeficiency virus type 1: distinct patterns of viral growth are determined by T-cell types. J. Virol. 65:4350-4358.
44. Rousseau, C., E. Abrams, M. Lee, R. Urbano, and M.-C. King. 1997. Long terminal repeat and nef gene variants of human immunodeficiency virus type 1 in perinatally infected long-term survivors and rapid progressors. AIDS Res. Hum. Retroviruses 13:1611-1623.
45. Saffer, J. D., S. P. Jackson, and S. J. Thurston. 1990. SV40 stimulates expression of the trans-acting factor Sp1 at the mRNA level. Genes Dev. 4:659-666.
46. Shibata, R., C. Siemon, S. C. Czajak, R. C. Desrosiers, and M. A. Martin. 1997. Live, attenuated simian immunodeficiency virus vaccines elicit potent resistance against a challenge with a human immunodeficiency virus type 1 chimeric virus. J. Virol. 71:8141-8148.
47. Smith, S. M., R. B. Markham, and K.-T. Jeang. 1996. Conditional reduction of human immunodeficiency virus type 1 replication by a gain-of-herpes simplex virus 1 thymidine kinase function. Proc. Natl. Acad. Sci. USA 93: 7955-7960.
48. Stahl-Hennig, C., U. Dittmer, T. Nisslein, H. Petry, Jurkiewicz, D. Fuchs, H. Wachter, K. Matz-Rensing, E. M. Kuhn, F. J. Kaup, E. W. Rud, and G. Hunsmann. 1996. Rapid development of vaccine protection in macaques by live-attenuated simian immunodeficiency virus. J. Gen. Virol. 77:2969-2981.
49. Sune, C., and M. A. Garcia-Blanco. 1995 Sp1 transcription factor is required for in vitro basal and Tat-activated transcription from the human immuno-deficiency virus type 1 long terminal repeat. J. Virol. 69:6572-6576.
50. Taddeo, B., F. Carlini, P. Verani, and A. Engelman. 1996. Reversion of a human immunodeficiency virus type 1 integrase mutant at a second site restores enzyme function and virus infectivity. J. Virol. 70:8277-8284.
51. Temin, H. M. 1993. A proposal for a new approach to a preventive vaccine against human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA 90: 4419-4420.
52. Trono, D. 1995. HIV accessory proteins: leading roles for the supporting cast. Cell 82:189-192.
53. Tsichlis, P. N., and P. A. Lazo. 1991. Virus-host interactions and the patho-genesis of murine and human oncogenic retroviruses, p. 95-171. In H. J. Kung and P. K. Vogt (ed.), Retroviral insertion and oncogene activation. Springer-Verlag KG, Berlin, Germany.
54. van Rompay, K. K. A., A. Spinner, M. Otsyula, M. B. McChesney, and M. L. Marthas. 1995. Attenuated retrovirus vaccines and AIDS. Science 270:1218.
55. Verhoef, K, M. Koper, and B. Berkhout. 1997. Determination of the minimal amount of Tat activity required for human immunodeficiency virus type 1 replication. Virology 237:228-236.
56. Whatmore, A. M., N. Cook, G. A. Hall, S. Sharpe, E. W. Rud, and M. P. Cranage. 1995. Repair and evolution of nef in vivo modulates simian immu-nodeficiency virus virulence. J. Virol. 69:5117-5123.
57. Willey, R. L, E. K. Ross, A. J. Buckler-White, T. S. Theodore, and M. A. Martin. 1989. Functional interaction of constant and variable domains of human immunodeficiency virus type gp120. J. Virol. 63:3595-3600.
58. Wyand, M. S., K. H. Manson, M. Garcia-Moll, D. Montefiori, and R. C. Desrosiers. 1996. Vaccine protection by a triple deletion mutant of simian immunodeficiency virus. J. Virol. 70:3724-3733.
59. Wyand, M. S., K. H. Manson, A. A. Lackner, and R. C. Desrosiers. 1997 Resistance of neonatal monkeys to live attenuated vaccine strains of simian immunodeficiency virus. Nat. Med. 3:32-36.
60. Zennou, V., F. Mammano, S. Paulous, D. Mathez, and F. Clavel. 1998. Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo. J. Virol. 72:3300-3306.